EGFR and neoplasm: In contrast to the resistance of the tumor organoids to chemotherapy drugs, multiple targeted agents showed good to exceptional activity, including the BTK inhibitor, ibrutinib (SPM score 97.3) and the EGFR inhibitor, afatinib (SPM score 95.9).